ABT-239

Drugbox
IUPAC_name = 4-(2-{2- [(2"R")-2-Methylpyrrolidin-1-yl] ethyl}-
benzofuran-5-yl)benzonitrile

---

CAS_number=
ATC_prefix=
ATC_suffix=
PubChem= 9818903
DrugBank=
C=22 | H=22 | N=2 | O=1
molecular_weight = 330.42 g/mol
smiles = N#Cc4ccc(cc4)-c3ccc2oc(cc2c3)CCN1CCCC1C
bioavailability=
metabolism =
elimination_half-life=
excretion =
pregnancy_category =
legal_status =
routes_of_administration=

ABT-239 is an H₃-receptor inverse agonist developed by Abbott. It has stimulant and nootropic effects, and has been investigated as a treatment for ADHD, Alzheimer's disease, and schizophrenia.cite journal | author = Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA | title = Pharmacological properties of ABT-239 [4-(2-{2- [(2R)-2-Methylpyrrolidinyl] ethyl}-benzofuran-5-yl)benzonitrile] : I. Potent and selective histamine H₃ receptor antagonist with drug-like properties | journal = J. Pharmacol. Exp. Ther. | volume = 313 | issue = 1 | pages = 165–75 | year = 2005 | pmid = 15608078 | doi = 10.1124/jpet.104.078303 | issn = ] cite journal | author = Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA | title = Pharmacological properties of ABT-239 [4-(2-{2- [(2R)-2-Methylpyrrolidinyl] ethyl}-benzofuran-5-yl)benzonitrile] : II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H₃ receptor antagonist | journal = J. Pharmacol. Exp. Ther. | volume = 313 | issue = 1 | pages = 176–90 | year = 2005 | pmid = 15608077 | doi = 10.1124/jpet.104.078402 | issn = ] cite journal | author = Cowart M, Faghih R, Curtis MP, Gfesser GA, Bennani YL, Black LA, Pan L, Marsh KC, Sullivan JP, Esbenshade TA, Fox GB, Hancock AA | title = 4-(2- [2-(2(R)-methylpyrrolidin-1-yl)ethyl] benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H₃ receptor antagonists potently enhance cognition and attention | journal = J. Med. Chem. | volume = 48 | issue = 1 | pages = 38–55 | year = 2005 | pmid = 15634000 | doi = 10.1021/jm040118g | issn = ] cite journal | author = Le S, Gruner JA, Mathiasen JR, Marino MJ, Schaffhauser H | title = Correlation between "ex vivo" receptor occupancy and wake-promoting activity of selective H₃ receptor antagonists | journal = J. Pharmacol. Exp. Ther. | volume = 325 | issue = 3 | pages = 902–9 | year = 2008 | month = June | pmid = 18305012 | doi = 10.1124/jpet.107.135343 | url = | issn = ] ABT-239 is more active at the human H₃ receptor than comparable agents such as thioperamide, ciproxifan, and cipralisant. It was ultimately dropped from human trials after showing the dangerous cardiac side effect of QT prolongation, [Hancock AA. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. "Biochemical Pharmacology". 2006 Apr 14;71(8):1103-13. PMID 16513092] but is still widely used in animal research into H₃ antagonists / inverse agonists.

References

External links

*MeshName|4-(2-(2-(2-methyl-1-pyrrolidinyl)ethyl)-1-benzofuran-5-yl)benzonitrile